• Abstracts can only be submitted online.
• We discourage splitting data from one study into several abstracts (“salami-slicing”) unless the amount of data cannot be condensed into a single abstract. In the submission form, authors must indicate whether there are several abstracts related to a single study.
• Abstracts should not be submitted if the following applies:
  • the abstract has been published or accepted for publication in a print or online journal before the abstract deadline (15 January 2024). Publication of the abstract in a scientific journal after the submission deadline is not in conflict with presenting it at EULAR conference 2024.
  • the abstract was presented at a scientific meeting more than 12 months prior to EULAR 2024.
• Abstracts accepted for the congress are subject to the “EULAR Embargo rules”*. With the submission of an abstract, the authors agree to the embargo rules.

Submissions from Russia and Belarus-based institutions or authors will not be accepted for EULAR 2024.

*Coming soon

• Abstract submission must be in one of the different tracks:

A. Basic and translational research

B. Clinical research
C. Health Professionals in Rheumatology (HPR)
D. Patient perspective (PARE)
E. Paediatric Rheumatology (PAED)

Important: Case reports or small case series must NOT be submitted via the regular abstract but via the call for clinical case reports.

In tracks A and B, the categories are subdivided into 27 abstract topics by disease. The correct track and disease must be selected to ensure correct scoring. This does not apply to track E (PAED).

Tracks C and D have their own subcategories.

See all topics, subcategories here.

• We have introduced the use of “Keywords” in the submission process. All submitted abstracts are mandated to select at least one and a maximum of 3 keywords in the list provided on the submission page. These keywords should be related to your abstract.
• Submitted scientific abstracts should only contain original data. Splitting of data originating from the same study across several abstracts and/or topics is not permitted and will lead to rejection of the abstracts.
• The inclusion of trade names/brand names is NOT allowed in the abstract, including statistical programmes or other, unless this is peculiar and adds value to their work. The mentioning of agents/molecules must follow the scientific standard for publications.
• For clinical abstract submissions, the presenting author can be any of the listed authors without affiliations to industry. For basic, translational and clinical studies below Phase 2, the presenting author can be any of the listed authors.
• Conflict of interest: It is the intent of EULAR to provide high quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during the abstracts' submission.

• It is mandatory to use the abstract word template provided by the system. Please read all instructions carefully before preparing your abstract. We recommend limiting your abstract to 55 lines.
   
• Counting towards the 3600 characters:
• Abstract title (minimum 15, maximum 300 characters)
• Headings and content of the abstract template, structured into the following sections:
  • a. Background
  • b. Objectives
  • c. Methods
  • d. Results
  • e. Conclusions
  • f. References (optional)

• Characters not counted, but part of final abstract:
  • Author first names, middle initials and last names
  • Author affiliations
  • Acknowledgements including working group
  • Working group + "on behalf of" if entered
  • Abstract number
  • DOI (Declaration of conflict of interest)
  • Invisible characters such as spaces
     
• Tables (characters included count): A maximum of 1 table (or two if no figure/graph/image is included) is allowed in the abstract word template with the following criteria: Combined maximum number of columns:12 / rows:20.
• Figure / Graphs / Images: A maximum of 1 figure or graph or image (or two if no table is included) is allowed. Tables turned into pictures/images are accepted, but should have sufficient quality that everything is readable.
• Abstracts can be re-edited and modified until the submission deadline. After the submission deadline, NO modification will be accepted by the EULAR team.

• Abstracts will be reviewed blinded. The reviewers will judge the abstracts according to the scientific or clinical value, relevance to EULAR, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.
   
• Abstract acceptance will be in one of four categories:
  • Oral presentation
  • Poster tour presentation,
  • Poster view display
  • Publication only
     
• Licence agreement: The authors, represented by the presenting author, will have to sign an agreement to grant EULAR the right to use the entire presentation (slides, video and audio recording during the conference) during the congress and subsequently for (paid or unpaid) educational purposes.
   
• Abstracts not adhering to these guidelines will be rejected. If you do not agree with any of these rules, you should not submit an abstract. The final decision about acceptance of an abstract will be taken by the EULAR Scientific Programme Committee. EULAR does not communicate, nor enter into correspondence on the reasons for acceptance/rejection of an abstract.

• Accepted abstracts will be published in a supplement to the Annals of Rheumatic Diseases (ARD). Information on accepted abstracts (title and authors) will also be available online about two weeks prior to the congress. Published abstracts will be available in the EULAR Abstract Archive during and after the congress.

• The submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session and the time assigned by the EULAR Scientific Programme Committee. We therefore recommend submitters of abstracts to register for the congress at the time of abstract submission.

• Change of presenting author: The presenting author may be changed through the EULAR congress system by the abstract submitter also after the abstract submission dateline but no later than 03 April 2024.

• If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to the abstract help desk at congress.abs@eular.org no later than 01 April 2024.

• Please note that all accepted abstracts for oral, poster tour and poster view presentations will be required to have the presenting authors present physically in Vienna. If, unexpectedly, the presenting author is unable to attend the congress, he or she would need to assign a co-author to present the abstract onsite.
   
• If the presenting author needs a letter of invitation for their visa application, they need to log in to their valid EULAR congress account - where their valid registration ticket to the congress has been purchased - and request a letter via the system. The registration team will provide them with the letter once requested. If the registration has been done by a third party, they can request a visa letter of invitation on behalf of the presenting author.
   
• Failure to be onsite at the assigned day and time of presentation will result with abstract being completely removed from the EULAR Abstract Archive and Abstract Book.
   
• Only presenting authors are eligible for Travel Bursaries. Please note that:
  • this is a separate process and requires a separate application to be made.
  • bursary awards are strictly non-transferrable to co-authors, neither for a next year use.
     
• Please note that Travel Bursary application opens on 1 October 2023 and closes on 31 January 2024. No further extension will be granted after the submission closes. Bursary can only be submitted via the online congress system.

The internet abstract submission system works best with Internet Explorer 10.0 or higher and Mozilla Firefox 5.0 or higher and Chrome 16 and Apple Safari 3 or higher.

Cookies and JavaScript need to be enabled. Recommended minimum desktop resolution is 1280 by 800 pixels